1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Sage Faces Multiple Moments Of Truth For Zuranolone, GABA Modulation

Parkinson’s Data For NMDA Modulator Also On Tap Before Year’s End

 
• By Mandy Jackson

Before pivotal depression data in 2021 attempt to redeem zuranolone after a failed Phase III study, the company will report Phase II results for next-gen GABA modulator SAGE-324 in essential tremor.

A man standing on top of a mountain as the sun sets
Sage may get a shot at redemption with zuranolone in depression • Source: Shutterstock

Three pivotal studies reading out in 2021 could redeem Sage Therapeutics, Inc.’s zuranolone (SAGE-217) following its failure in the acute treatment of major depressive disorder at the end of last year. Before then, however, Phase II results for its next-generation drug SAGE-324 in chronic treatment of essential tremor could reinforce the company’s confidence in its GABA-modulation approach to mood and movement disorders.

Three Phase III clinical trials of zuranolone are under way in two different major depressive disorder (MDD) settings and in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

US FDA Backing Is A Breakthrough For Taysha’s Gene Therapy

 
• By Andrew McConaghie

The regulator has agreed to a six-month preliminary analysis of its pivotal study which could accelerate filing of TSHA-102 for Rett syndrome.

HMNC Pushes On With Biomarker-Driven Depression Drug After Setback

 
• By Sushmita Panda

By combining novel drug mechanisms with genetic biomarkers, HMNC Brain Health hopes to transform depression care.

Orion Shrugs Off Insomnia Drug Failure

 
• By Andrew McConaghie

A second pipeline setback within a year for the Finland-based firm has not dented optimism about its growth trajectory.

Larimar Proceeding Toward Accelerated Approval Filing In Friedreich’s Ataxia

 
• By Joseph Haas

Larimar reported data from an ongoing open-label study with its protein therapy in FA, showing encouraging skin frataxin levels, but shareholders walked away due to safety worries.

More from Therapy Areas

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

 
• By Joseph Haas

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

Boehringer’s Jascayd Approval Brings New Mechanism To IPF

 
• By Jessica Merrill

The PDE4B inhibitor brings a new mechanism of action to the challenging respiratory disease and is the first drug approved for the indication in more than a decade.

Valneva Secures $500m Financing Ahead Of Lyme Disease Vaccine Readout

 
• By Kevin Grogan

The France-based firm shrugs off the disappointment of the FDA's suspension of Ixchiq.